Publications

Editorial Epublish

PubMed: 40365397 DOI: 10.1021/acsmedchemlett.5c00197

Novel Isoxazolidines Derivatives as RIPK1 Inhibitors for Treating Neurodegenerative Diseases.

ACS Med Chem Lett 16(5):754-755

Authors: Ram W Sabnis

Affiliations

  • Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309 United States.

Abstract

Provided herein are novel isoxazolidines derivatives as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating neurodegenerative diseases, and processes for preparing such compounds.

MeSH

Neurodegenerative Diseases